1. Home
  2. BILL vs IMNM Comparison

BILL vs IMNM Comparison

Compare BILL & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BILL Holdings Inc.

BILL

BILL Holdings Inc.

HOLD

Current Price

$45.09

Market Cap

3.2B

Sector

Technology

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$22.16

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BILL
IMNM
Founded
2006
2006
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.6B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
BILL
IMNM
Price
$45.09
$22.16
Analyst Decision
Buy
Strong Buy
Analyst Count
21
10
Target Price
$57.90
$32.80
AVG Volume (30 Days)
2.4M
1.7M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
74.07
51.40
EPS
0.07
N/A
Revenue
$1,462,570,000.00
$6,941,000.00
Revenue This Year
$14.18
N/A
Revenue Next Year
$13.83
$1,127.34
P/E Ratio
$640.29
N/A
Revenue Growth
13.36
N/A
52 Week Low
$31.41
$8.67
52 Week High
$57.21
$27.65

Technical Indicators

Market Signals
Indicator
BILL
IMNM
Relative Strength Index (RSI) 72.04 53.56
Support Level $42.06 $19.28
Resistance Level $46.70 $23.25
Average True Range (ATR) 1.76 1.31
MACD 0.73 -0.07
Stochastic Oscillator 91.00 36.55

Price Performance

Historical Comparison
BILL
IMNM

About BILL BILL Holdings Inc.

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: